Grace Therapeutics, Inc. (GRCE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $38.08M
Last updated: Nov 17, 2026 at 11:04 AM ET
Grace Therapeutics, Inc. (GRCE) Stock Forecast
Analysts expect Grace Therapeutics (GRCE) to earn -$0.76 per share in the fiscal year ending Mar 31, 2027. Over the last 30 days, 0 estimates for the fiscal year ending Mar 31, 2027 were revised up and 1 down. For the fiscal year ending Mar 31, 2028, the EPS consensus is -$0.60.
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Mar 31, 2027
- -$0.76
- EPS consensus
- Fiscal year ending Mar 31, 2028
- -$0.60
- EPS consensus
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Mar 31, 2027 | -$0.76 | -$0.76 to -$0.76 | 1 |
| Mar 31, 2028 | -$0.60 | -$0.60 to -$0.60 | 1 |
Quarterly Estimates
The EPS consensus rises from -$0.21 for the quarter ending Dec 31, 2026 to -$0.12 for the quarter ending Mar 31, 2027.
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.21 | -$0.21 to -$0.21 | 1 |
| Mar 31, 2027 | -$0.12 | N/A | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 1 upward and 3 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Mar 31, 2027 | 0 | 1 |
| Fiscal year ending Mar 31, 2028 | 1 | 1 |
| Quarter ending Dec 31, 2026 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Mar 31, 2027 has worsened from -$0.74.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Mar 31, 2027 | -$0.76 | -$0.76 | -$0.76 | -$0.76 | -$0.74 | N/A |
| Fiscal year ending Mar 31, 2028 | -$0.60 | -$0.64 | -$0.64 | -$0.64 | -$0.77 | N/A |
| Quarter ending Dec 31, 2026 | -$0.21 | -$0.18 | -$0.18 | -$0.21 | -$0.21 | N/A |
Frequently Asked Questions About GRCE
What is the GRCE stock forecast?
Consensus analyst estimates put Grace Therapeutics's EPS at -$0.76 for the fiscal year ending Mar 31, 2027.
What EPS do analysts expect from GRCE next year?
For the fiscal year ending Mar 31, 2027, the consensus EPS estimate is -$0.76, with estimates from -$0.76 to -$0.76 from 1 analyst. For the fiscal year ending Mar 31, 2028, the consensus EPS estimate is -$0.60, with estimates from -$0.60 to -$0.60 from 1 analyst.
How many analysts cover GRCE?
1 analyst estimates EPS for Grace Therapeutics for the fiscal year ending Mar 31, 2027.
GRCE pages: Overview, Earnings, Forecast, Financials, Competitors